RMRaviKanthReddy Marreddy

RaviKanthReddy Marreddy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


RaviKanthReddy Marreddy has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Dianqing Sun

    Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, 34 Rainbow Drive, Hilo, Hawaii 96720, United States

    3 shared publications
  • Joao P. C. Pinto

    Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, The Netherlands

    3 shared publications
  • Julian G. Hurdle

    Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center

    3 shared publications
  • Allan M. Prior

    Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii, 96720, United States

    2 shared publications
  • Bert Poolman

    Department of Biochemistry, Groningen Biomolecular Sciences and Biotechnology Institute, Netherlands Proteomics Centre & Zernike Institute for Advanced Materials University of Groningen, Groningen, The Netherlands

    2 shared publications
  • Eric. R. Geertsma

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany

    2 shared publications

Latest Publications

  • Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity

    by Jesse A. Jones, Allan M. Prior, Ravi K. R. Marreddy, Rebecca D. Wahrmund, Julian G. Hurdle, Dianqing Sun, Kirk E. Hevener

    Clostridioides difficile infection (CDI) is a leading cause of significant morbidity, mortality, and healthcare-related costs in the United States. After standard therapy, recurrence rates remain high, and multiple recurrences are not uncommon. Causes include treatments employing broad-spectrum agents that disrupt the normal host microbiota, as well as treatment-resistant spore formation by C. difficile. Thus, novel druggable anti-C. difficile targets that promote narrow-spectrum eradication and inhibition of sporulation are desired. As a critical rate-limiting step within the FAS-II bacterial fatty acid synthesis pathway, which supplies precursory component phospholipids found in bacterial cytoplasmic and spore-mediated membranes, enoyl-acyl carrier protein (ACP) reductase II (FabK) represents such a target. FabK is essential in C. difficile (CdFabK) and is structurally and mechanistically distinct from other isozymes found in gut microbiota species, making CdFabK an attractive narrow-spectrum target. We report here the kinetic evaluation of CdFabK, the biochemical activity of a series of phenylimidazole analogues, and microbiological data suggesting these compounds’ selective antibacterial activity against C. difficile versus several other prominent gut organisms. The compounds display promising, selective, low micromolar CdFabK inhibitory activity without significantly affecting the growth of other gut organisms, and the series prototype (1b) is shown to be competitive for the CdFabK cofactor and uncompetitive for the substrate. A series analogue (1g) shows maintained inhibitory activity while also possessing increased solubility. These findings represent the basis for future drug discovery efforts by characterizing the CdFabK enzyme while demonstrating its druggability and potential role as a narrow-spectrum antidifficile target.


  • The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection

    by RaviKanthReddy Marreddy, Xiaoqian Wu, Madhab Sapkota, Allan M. Prior, Jesse A. Jones, Dianqing Sun, Kirk E. Hevener, Julian G. Hurdle

    Clostridium difficile infection (CDI) is an antibiotic-induced microbiota shift disease of the large bowel. While there is a need for narrow-spectrum CDI antibiotics, it is unclear which cellular proteins are appropriate drug targets to specifically inhibit C. difficile. We evaluated the enoyl-acyl carrier protein reductase II (FabK) that catalyzes the final step of bacterial fatty acid biosynthesis. Bioinformatics showed C. difficile uses FabK as its sole enoyl-ACP reductase, unlike several major microbiota species. The essentiality of fabK for C. difficile growth was confirmed by failure to delete this gene using Clostron mutagenesis and by growth inhibition upon gene silencing with CRISPR-interference antisense to fabK transcription or by blocking protein translation. Inhibition of C. difficile’s FASII pathway could not be circumvented by supply of exogenous fatty acids, either during fabK’s gene silencing or upon inhibition of the enzyme with a phenylimidazole-derived inhibitor 1. The inability for fatty acids to bypass FASII inhibition is likely due to the function of transcriptional repressor FapR. Inhibition of FabK also inhibited spore formation, reflecting the enzyme’s role in de novo fatty acid biosynthesis for the formation of spore membrane lipids. Compound 1 did not inhibit growth of key microbiota species. These findings suggest that C. difficile FabK is a druggable target for discovering narrow-spectrum anti-C. difficile drugs to treat CDI but avoid collateral damage to the gut microbiota.


  • New β-lactam – Tetramic acid hybrids show promising antibacterial activities

    by Philip T. Cherian, Martin N. Cheramie, Ravi K.R. Marreddy, Dinesh M. Fernando, Julian G. Hurdle, Richard E. Lee


  • Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs

    by Lissa S. Tsutsumi, John M. Elmore, Uyen T. Dang, Miranda J. Wallace, Ravikanthreddy Marreddy, Robin B. Lee, Ghee T. Tan, Julian G. Hurdle, Richard E. Lee, Dianqing Sun

    Herein we report the antibacterial structure-activity relationships of cyclic hexapeptide wollamide analogs derived from solid-phase library synthesis. Wollamide B, a cyclic hexapeptide natural product, has been previously found to have activity against Mycobacterium bovis. To further evaluate its antimycobacterial/antibacterial potential, 27 peptides including wollamides A/B, and desotamide B, were synthesized and subsequently tested against a panel of clinically significant bacterial pathogens. Biological evaluation revealed that the cyclic scaffold, amide functionality in position I, tryptophan residue in position V, and the original stereochemistry pattern of the core scaffold were key for antituberculosis and/or antibacterial activity. In addition, against M. tuberculosis and Gram-positive bacteria, residues in position II and/or VI greatly impacted antibacterial activity and selectivity. Wollamides A (3) and B (2) along with their corresponding II (L-Leu) analog 10 retained the most promising antituberculosis activity, with the lowest minimum inhibitory concentration (MIC) against virulent M. tuberculosis H37Rv (MIC = 1.56 µg/mL) as well as desirable selectivity indices (>100). Importantly, the antimicrobial activities of wollamides A and B do not result from disruption of the bacterial membrane, warranting further investigation into their mechanism of action.


  • Biophysical characterization of E. coli TolC interaction with the known blocker hexaamminecobalt

    by A. Gilardi, S.P. Bhamidimarri, M. Brönstrup, U. Bilitewski, R.K.R. Marreddy, K.M. Pos, L. Benier, P. Gribbon, M. Winterhalter, B. Windshügel


  • Open Access

    Tripartite assembly of RND multidrug efflux pumps

    by Laetitia Daury, François Orange, Jean-Christophe Taveau, Alice Verchère, Laura Monlezun, Céline Gounou, Ravi K. R. Marreddy, Martin Picard, Isabelle Broutin, Klaas M. Pos, et al.

    Tripartite multidrug efflux systems of Gram-negative bacteria are composed of an inner membrane transporter, an outer membrane channel and a periplasmic adaptor protein. They are assumed to form ducts inside the periplasm facilitating drug exit across the outer membrane. Here we present the reconstitution of native Pseudomonas aeruginosa MexAB–OprM and Escherichia coli AcrAB–TolC tripartite Resistance Nodulation and cell Division (RND) efflux systems in a lipid nanodisc system. Single-particle analysis by electron microscopy reveals the inner and outer membrane protein components linked together via the periplasmic adaptor protein. This intrinsic ability of the native components to self-assemble also leads to the formation of a stable interspecies AcrA–MexB–TolC complex suggesting a common mechanism of tripartite assembly. Projection structures of all three complexes emphasize the role of the periplasmic adaptor protein as part of the exit duct with no physical interaction between the inner and outer membrane components.


  • Open Access

    The Response of Lactococcus lactis to Membrane Protein Production

    by Ravi K. R. Marreddy, Joao P. C. Pinto, Justina C. Wolters, Eric R. Geertsma, Fabrizia Fusetti, Hjalmar P. Permentier, Oscar P. Kuipers, Jan Kok, Bert Poolman

    The biogenesis of membrane proteins is more complex than that of water-soluble proteins, and recombinant expression of membrane proteins in functional form and in amounts high enough for structural and functional studies is often problematic. To better engineer cells towards efficient protein production, we set out to understand and compare the cellular consequences of the overproduction of both classes of proteins in Lactococcus lactis, employing a combined proteomics and transcriptomics approach. Highly overproduced and poorly expressed membrane proteins both resulted in severe growth defects, whereas amplified levels of a soluble substrate receptor had no effect. In addition, membrane protein overproduction evoked a general stress response (upregulation of various chaperones and proteases), which is probably due to accumulation of misfolded protein. Notably, upon the expression of membrane proteins a cell envelope stress response, controlled by the two-component regulatory CesSR system, was observed. The physiological response of L. lactis to the overproduction of several membrane proteins was determined and compared to that of a soluble protein, thus offering better understanding of the bottlenecks related to membrane protein production and valuable knowledge for subsequent strain engineering.


  • Open Access

    Efficient Overproduction of Membrane Proteins in Lactococcus lactis Requires the Cell Envelope Stress Sensor/Regulator Couple CesSR

    by Joao P. C. Pinto, Oscar P. Kuipers, Ravi K. R. Marreddy, Bert Poolman, Jan Kok

    Membrane proteins comprise an important class of molecules whose study is largely frustrated by several intrinsic constraints, such as their hydrophobicity and added requirements for correct folding. Additionally, the complexity of the cellular mechanisms that are required to insert membrane proteins functionally in the membrane and to monitor their folding state makes it difficult to foresee the yields at which one can obtain them or to predict which would be the optimal production host for a given protein. We describe a rational design approach to improve the lactic acid bacterium Lactococcus lactis as a producer of membrane proteins. Our transcriptome data shows that the two-component system CesSR, which senses cell envelope stresses of different origins, is one of the major players when L. lactis is forced to overproduce the endogenous membrane protein BcaP, a branched-chain amino acid permease. Growth of the BcaP-producing L. lactis strain and its capability to produce membrane proteins are severely hampered when the CesSR system itself or particular members of the CesSR regulon are knocked out, notably the genes ftsH, oxaA2, llmg_2163 and rmaB. Overexpressing cesSR reduced the growth defect, thus directly improving the production yield of BcaP. Applying this rationale to eukaryotic proteins, some of which are notoriously more difficult to produce, such as the medically-important presenilin complex, we were able to significantly diminish the growth defect seen in the wild-type strain and improve the production yield of the presenilin variant PS1Δ9-H6 more than 4-fold. The results shed light into a key, and perhaps central, membrane protein quality control mechanism in L. lactis. Modulating the expression of CesSR benefited the production yields of membrane proteins from different origins. These findings reinforce L. lactis as a legitimate alternative host for the production of membrane proteins.


  • Open Access

    Amino Acid Accumulation Limits the Overexpression of Proteins in Lactococcus lactis

    by Ravi K. R. Marreddy, Eric R. Geertsma, Hjalmar P. Permentier, Joao P. C. Pinto, Jan Kok, Bert Poolman

    Understanding the biogenesis pathways for the functional expression of recombinant proteins, in particular membrane proteins and complex multidomain assemblies, is a fundamental issue in cell biology and of high importance for future progress in structural genomics. In this study, we employed a proteomic approach to understand the difference in expression levels for various multidomain membrane proteins in L. lactis cells grown in complex and synthetic media. The proteomic profiles of cells growing in media in which the proteins were expressed to high or low levels suggested a limitation in the availability of branched-chain amino acids, more specifically a too limited capacity to accumulate these nutrients. By supplying the cells with an alternative path for accumulation of Ile, Leu and/or Val, i.e., a medium supplement of the appropriate dipeptides, or by engineering the transport capacity for branched-chain amino acids, the expression levels could be increased several fold. We show that the availability of branched chain amino acids is a critical factor for the (over)expression of proteins in L. lactis. The forward engineering of cells for functional protein production required fine-tuning of co-expression of the branched chain amino acid transporter.